Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase EARLY_PHASE1 4Phase NA 3Phase 1/2 2Phase 4 1Phase 2/3 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Leukemia, Myeloid, Acute 1Glioblastoma 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Spironolactone × Clear all
NCT07431216 2026-03-30

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

Starlight Therapeutics Inc.

Phase 1/2 Not yet recruiting
68 enrolled
CNS

Glioblastoma

NCT03867682 2023-08-04

Venetoclax and Lintuzumab-Ac225 in AML Patients

Actinium Pharmaceuticals

Phase 1/2 Unknown
38 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡